Carolyn M Clark1, Antonieta Guerrero-Plata1,2. 1. Department of Pathobiological Sciences, Louisiana State University, Baton Rouge, LA 70803, USA. 2. Center for Experimental Infectious Disease Research, Louisiana State University, Baton Rouge, LA 70803, USA.
Abstract
PURPOSE OF REVIEW: Respiratory syncytial virus (RSV) is a global human pathogen responsible for lower respiratory tract infections (LRTI). While RSV infection is innocuous in healthy adults, it is the leading cause of infant hospitalization for respiratory tract infection. Nearly everyone shows evidence of an RSV infection by the age of 3. However, there is still not a vaccine commercially available. This review will provide an update on the clinical and preclinical vaccine studies and different approaches to prevent RSV infection. RECENT FINDINGS: Novel vaccine approaches that induce protection against RSV without enhancement of respiratory tract disease. SUMMARY: Recent technological approaches have led to generation of different strategies to prevent RSV infection, including live attenuated, chimeric, and subunit vaccines, virus-like particles, and nanoparticles. These vaccine approaches represent promising candidates towards an efficient RSV vaccine that effectively protects infants, children, and adults.
PURPOSE OF REVIEW: Respiratory syncytial virus (RSV) is a global human pathogen responsible for lower respiratory tract infections (LRTI). While RSV infection is innocuous in healthy adults, it is the leading cause of infant hospitalization for respiratory tract infection. Nearly everyone shows evidence of an RSV infection by the age of 3. However, there is still not a vaccine commercially available. This review will provide an update on the clinical and preclinical vaccine studies and different approaches to prevent RSV infection. RECENT FINDINGS: Novel vaccine approaches that induce protection against RSV without enhancement of respiratory tract disease. SUMMARY: Recent technological approaches have led to generation of different strategies to prevent RSV infection, including live attenuated, chimeric, and subunit vaccines, virus-like particles, and nanoparticles. These vaccine approaches represent promising candidates towards an efficient RSV vaccine that effectively protects infants, children, and adults.
Authors: Pablo F Céspedes; Emma Rey-Jurado; Janyra A Espinoza; Claudia A Rivera; Gisela Canedo-Marroquín; Susan M Bueno; Alexis M Kalergis Journal: Vaccine Date: 2017-01-05 Impact factor: 3.641
Authors: Bo Liang; Joan O Ngwuta; Sonja Surman; Barbora Kabatova; Xiang Liu; Matthias Lingemann; Xueqiao Liu; Lijuan Yang; Richard Herbert; Joanna Swerczek; Man Chen; Syed M Moin; Azad Kumar; Jason S McLellan; Peter D Kwong; Barney S Graham; Peter L Collins; Shirin Munir Journal: J Virol Date: 2017-07-12 Impact factor: 5.103
Authors: Margarita Magro; Vicente Mas; Keith Chappell; Mónica Vázquez; Olga Cano; Daniel Luque; María C Terrón; José A Melero; Concepción Palomo Journal: Proc Natl Acad Sci U S A Date: 2012-02-08 Impact factor: 11.205
Authors: Jason S McLellan; Man Chen; Sherman Leung; Kevin W Graepel; Xiulian Du; Yongping Yang; Tongqing Zhou; Ulrich Baxa; Etsuko Yasuda; Tim Beaumont; Azad Kumar; Kayvon Modjarrad; Zizheng Zheng; Min Zhao; Ningshao Xia; Peter D Kwong; Barney S Graham Journal: Science Date: 2013-04-25 Impact factor: 47.728
Authors: Gregory M Glenn; Louis F Fries; D Nigel Thomas; Gale Smith; Eloi Kpamegan; Hanxin Lu; David Flyer; Dewal Jani; Somia P Hickman; Pedro A Piedra Journal: J Infect Dis Date: 2015-08-10 Impact factor: 5.226
Authors: Christopher C Stobart; Christina A Rostad; Zunlong Ke; Rebecca S Dillard; Cheri M Hampton; Joshua D Strauss; Hong Yi; Anne L Hotard; Jia Meng; Raymond J Pickles; Kaori Sakamoto; Sujin Lee; Michael G Currier; Syed M Moin; Barney S Graham; Marina S Boukhvalova; Brian E Gilbert; Jorge C G Blanco; Pedro A Piedra; Elizabeth R Wright; Martin L Moore Journal: Nat Commun Date: 2016-12-21 Impact factor: 14.919